Wang H - Search Results

1

Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery.

Huang Y, Jiang Y, Wang H, Wang J, Shin MC, Byun Y, He H, Liang Y, Yang VC. Huang Y, et al. Among authors: wang h, wang j. Adv Drug Deliv Rev. 2013 Oct;65(10):1299-315. doi: 10.1016/j.addr.2012.11.007. Epub 2013 Jan 28. Adv Drug Deliv Rev. 2013. PMID: 23369828 Free PMC article. Review.

2

TAT-modified nanosilver for combating multidrug-resistant cancer.

Liu J, Zhao Y, Guo Q, Wang Z, Wang H, Yang Y, Huang Y. Liu J, et al. Among authors: wang h, wang z. Biomaterials. 2012 Sep;33(26):6155-61. doi: 10.1016/j.biomaterials.2012.05.035. Epub 2012 Jun 8. Biomaterials. 2012. PMID: 22682937

3

Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.

Wang H, Li F, Du C, Wang H, Mahato RI, Huang Y. Wang H, et al. Mol Pharm. 2014 Aug 4;11(8):2600-11. doi: 10.1021/mp400687w. Epub 2014 Jan 17. Mol Pharm. 2014. PMID: 24405470

4

Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.

Wang H, Zhao Y, Wang H, Gong J, He H, Shin MC, Yang VC, Huang Y. Wang H, et al. J Control Release. 2014 Oct 28;192:47-56. doi: 10.1016/j.jconrel.2014.06.051. Epub 2014 Jul 6. J Control Release. 2014. PMID: 25003794

5

Cell-penetrating apoptotic peptide/p53 DNA nanocomplex as adjuvant therapy for drug-resistant breast cancer.

Wang H, Wang H, Liang J, Jiang Y, Guo Q, Peng H, Xu Q, Huang Y. Wang H, et al. Mol Pharm. 2014 Oct 6;11(10):3352-60. doi: 10.1021/mp5001058. Epub 2014 Aug 13. Mol Pharm. 2014. PMID: 25080334

6

Molecular-dynamics-simulation-driven design of a protease-responsive probe for in-vivo tumor imaging.

Jiang Y, Lu J, Wang Y, Zeng F, Wang H, Peng H, Huang M, Jiang H, Luo C, Huang Y. Jiang Y, et al. Among authors: wang h, wang y. Adv Mater. 2014 Dec 23;26(48):8174-8. doi: 10.1002/adma.201403547. Epub 2014 Oct 22. Adv Mater. 2014. PMID: 25338710

7

Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors.

Wang H, Jiang Y, Peng H, Chen Y, Zhu P, Huang Y. Wang H, et al. Adv Drug Deliv Rev. 2015 Jan;81:142-60. doi: 10.1016/j.addr.2014.10.031. Epub 2014 Nov 7. Adv Drug Deliv Rev. 2015. PMID: 25450259 Review.

8

Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassembly to overcome drug-resistant colon cancer.

Pan ZZ, Wang HY, Zhang M, Lin TT, Zhang WY, Zhao PF, Tang YS, Xiong Y, Zeng YE, Huang YZ. Pan ZZ, et al. Acta Pharmacol Sin. 2016 Aug;37(8):1110-20. doi: 10.1038/aps.2016.48. Epub 2016 Jun 13. Acta Pharmacol Sin. 2016. PMID: 27292613 Free PMC article.

9

Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.

Chen Y, Zhang M, Jin H, Tang Y, Wang H, Xu Q, Li Y, Li F, Huang Y. Chen Y, et al. Among authors: wang h. Biomaterials. 2017 Feb;116:57-68. doi: 10.1016/j.biomaterials.2016.11.033. Epub 2016 Nov 27. Biomaterials. 2017. PMID: 27914267 Free PMC article.

10

Improved Protein Toxin Delivery Based on ATTEMPTS Systems.

Chen Y, Zhang M, Min KA, Wang H, Shin MC, Li F, Yang VC, Huang Y. Chen Y, et al. Among authors: wang h. Curr Drug Targets. 2018 Feb 19;19(4):380-392. doi: 10.2174/1389450118666170302094758. Curr Drug Targets. 2018. PMID: 28260497 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152,134 results

Search Page

Filters